Catalent, Inc. (CTLT)
USD 63.48
(0.0%)
USD 63.48
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 953 Million USD | -10.09% |
| 2023 | 1.06 Billion USD | -35.37% |
| 2022 | 1.64 Billion USD | 21.3% |
| 2021 | 1.35 Billion USD | 37.5% |
| 2020 | 983.3 Million USD | 22.13% |
| 2019 | 805.1 Million USD | 6.98% |
| 2018 | 752.6 Million USD | 14.97% |
| 2017 | 654.6 Million USD | 11.4% |
| 2016 | 587.6 Million USD | -4.5% |
| 2015 | 615.3 Million USD | 2.79% |
| 2014 | 598.6 Million USD | 5.28% |
| 2013 | 568.6 Million USD | 1.79% |
| 2012 | 558.6 Million USD | 11.25% |
| 2011 | 502.1 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 171 Million USD | -5.52% |
| 2024 FY | 953 Million USD | -10.09% |
| 2024 Q3 | 229 Million USD | 33.92% |
| 2024 Q4 | 384 Million USD | 67.69% |
| 2024 Q1 | 181 Million USD | -22.98% |
| 2023 Q4 | 235 Million USD | 30.56% |
| 2023 Q3 | 180 Million USD | -53.49% |
| 2023 Q2 | 387 Million USD | 50.0% |
| 2023 FY | 1.06 Billion USD | -35.37% |
| 2023 Q1 | 258 Million USD | -47.13% |
| 2022 Q3 | 423 Million USD | 4.44% |
| 2022 FY | 1.64 Billion USD | 21.3% |
| 2022 Q1 | 324 Million USD | -26.2% |
| 2022 Q4 | 488 Million USD | 15.37% |
| 2022 Q2 | 405 Million USD | 25.0% |
| 2021 Q4 | 439 Million USD | 20.08% |
| 2021 FY | 1.35 Billion USD | 37.5% |
| 2021 Q3 | 365.6 Million USD | 22.6% |
| 2021 Q1 | 248.9 Million USD | -25.61% |
| 2021 Q2 | 298.2 Million USD | 19.81% |
| 2020 FY | 983.3 Million USD | 22.13% |
| 2020 Q3 | 238.8 Million USD | 2.84% |
| 2020 Q2 | 232.2 Million USD | 30.67% |
| 2020 Q4 | 334.6 Million USD | 40.12% |
| 2020 Q1 | 177.7 Million USD | -30.72% |
| 2019 FY | 805.1 Million USD | 6.98% |
| 2019 Q1 | 148.5 Million USD | -36.38% |
| 2019 Q2 | 201.4 Million USD | 35.62% |
| 2019 Q3 | 198.7 Million USD | -1.34% |
| 2019 Q4 | 256.5 Million USD | 29.09% |
| 2018 Q1 | 140.1 Million USD | -34.9% |
| 2018 Q4 | 233.4 Million USD | 21.75% |
| 2018 Q3 | 191.7 Million USD | 2.29% |
| 2018 Q2 | 187.4 Million USD | 33.76% |
| 2018 FY | 752.6 Million USD | 14.97% |
| 2017 Q2 | 147.9 Million USD | 19.18% |
| 2017 Q3 | 167.4 Million USD | 13.18% |
| 2017 Q4 | 215.2 Million USD | 28.55% |
| 2017 FY | 654.6 Million USD | 11.4% |
| 2017 Q1 | 124.1 Million USD | -33.92% |
| 2016 FY | 587.6 Million USD | -4.5% |
| 2016 Q2 | 152.1 Million USD | 25.19% |
| 2016 Q4 | 187.8 Million USD | 48.81% |
| 2016 Q1 | 121.5 Million USD | -33.13% |
| 2016 Q3 | 126.2 Million USD | -17.03% |
| 2015 FY | 615.3 Million USD | 2.79% |
| 2015 Q4 | 181.7 Million USD | 19.38% |
| 2015 Q1 | 125.3 Million USD | -34.16% |
| 2015 Q3 | 152.2 Million USD | -2.5% |
| 2015 Q2 | 156.1 Million USD | 24.58% |
| 2014 Q2 | 137.4 Million USD | 15.27% |
| 2014 FY | 598.6 Million USD | 5.28% |
| 2014 Q3 | 151.7 Million USD | 10.41% |
| 2014 Q1 | 119.2 Million USD | -31.38% |
| 2014 Q4 | 190.3 Million USD | 25.44% |
| 2013 Q3 | 137.4 Million USD | -1.86% |
| 2013 Q4 | 173.7 Million USD | 26.42% |
| 2013 FY | 568.6 Million USD | 1.79% |
| 2013 Q1 | 117.5 Million USD | 0.0% |
| 2013 Q2 | 140 Million USD | 19.15% |
| 2012 FY | 558.6 Million USD | 11.25% |
| 2011 FY | 502.1 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 820.56 Million USD | -16.139% |
| Bausch Health Companies Inc. | 6.19 Billion USD | 84.624% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -177.115% |
| Elanco Animal Health Incorporated | 2.48 Billion USD | 61.665% |
| Perrigo Company plc | 1.68 Billion USD | 43.287% |
| Teva Pharmaceutical Industries Limited | 7.64 Billion USD | 87.536% |
| Zoetis Inc. | 5.83 Billion USD | 83.665% |